Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 4/20 | 0.72 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.66 |
| ▸ | AR | P10275 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3864858 | 1.00 | SRD5A2 (0.72) | SRD5A2SRD5A1AR | |
| SCHEMBL14397354 | 0.89 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL28559933 | 0.89 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL14477867 | 0.89 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL14477862 | 0.89 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL950691 | 0.89 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL5907001 | 0.89 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL950693 | 0.89 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL13844000 | 0.89 | SRD5A2 (0.73) | SRD5A2SRD5A1AR | |
| SCHEMBL12423998 | 0.89 | SRD5A2 (0.73) | SRD5A2SRD5A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622567-B1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-1945615-A2 | PREPARATION OF DUTASTERIDE | Dr. Reddy's Laboratories Ltd. (IN) | 2008-07-23 | — | — | EP | disclosed |
| US-20080119503-A1 | Androgen receptor modulators and methods of use thereof | MERCK SHARP & DOHME CORP. | 2008-05-22 | — | — | US | disclosed |
| US-7351698-B2 | Androgen receptor modulators and methods of use thereof | MERCK & CO., INC. (US) | 2008-04-01 | — | — | US | disclosed |
| WO-2007120263-A2 | PREPARATION OF DUTASTERIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-10-25 | — | — | WO | disclosed |
| EP-1420796-A4 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO INC (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20060241107-A1 | Androgen receptor modulators and methods of use thereof | MERCK SHARP & DOHME LLC | 2006-10-26 | — | — | US | disclosed |
| EP-1420796-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Merck & Co., Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6645974-B2 | Administering an androstamide compound; osteoporosis, anticancer agents, glandular disorders | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | disclosed |
| WO-2003011302-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| EP-0547691-B1 | The use of 17B-N-mono-substituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones for the preparation of a medicament for the prevention of prostatic carcinoma | MERCK & CO INC (US) | 1997-03-19 | — | — | EP | disclosed |
| WO-1994022900-A1 | AZA-ANDROSTANE-17β-CARBOXAMIDES | CIBA-GEIGY AG (CH) | 1994-10-13 | — | — | WO | disclosed |
| EP-0285382-B1 | Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO INC (US) | 1994-04-13 | — | — | EP | disclosed |
| EP-0285383-B1 | Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO INC (US) | 1994-03-16 | — | — | EP | disclosed |
| EP-0547691-A1 | The use of 17B-N-mono-substituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones for the preparation of a medicament for the prevention of prostatic carcinoma | MERCK & CO. INC. (US) | 1993-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | AR, FSHR, SHBG | SRD5A2 80/4885SRD5A1 58/4885AR 1/4885 |
| US-20060241107-A1 | Androgen receptor modulators and methods of use thereof | SHBG, FSHR, AR | SRD5A2 57/4885SRD5A1 42/4885AR 3/4885 |
| US-20080119503-A1 | Androgen receptor modulators and methods of use thereof | SHBG, FSHR, AR | SRD5A2 57/4885SRD5A1 42/4885AR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.